Abstract
and 687pg/ml, respectively. BNP decreased in both groups at discharge (60% for MSASV vs. 40% for standard care). However, after 3 days, BNP in the standard care group had increased to a median of 920pg/ml, while BNP in the MV-ASV group demonstrated a continued and marked decrease to a median of 353pg/ml. Compared to admission, the 3 day Likert Breathing scores demonstrated an average 52% increase in the MV-ASV group, versus a 24% increase in the standard care group. Conclusion: The use of MV-ASV in patients with ADHF resulted in a rapid early improvement in dyspnea as well as a marked drop in BNP levels, suggesting mitigations of pulmonary edema and neurohormonal activity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
